Literature DB >> 17614850

Axillary lymph node micrometastases in invasive breast cancer: national figures on incidence and overall survival.

D Grabau1, M B Jensen, F Rank, M Blichert-Toft.   

Abstract

The purpose of this study was to estimate the incidence and prognostic value of axillary lymph node micrometastases (Nmic) of 2 mm or less in breast carcinomas. Results are based on data from the Danish Breast Cancer Cooperative Group (DBCG). The study was carried out as a nationwide, population-based trial with a study series consisting of 6,959 women under 75 years of age registered in the national DBCG data base from 1 January 1990 to 31 October 1994. All patients had contracted operable primary breast carcinoma, stage I-III, classified according to the TNM system as T1-T3, N0-N1, M0. Women with four or more metastatic axillary lymph nodes were excluded. All patients were treated systematically according to approved national guidelines and treatment protocols. Metastases were recognized microscopically on haematoxylin and eosin-stained sections. In case of doubt immunohistochemical staining for cytokeratin was performed. There was no serial sectioning. Micrometastases were tumour deposits of 2 mm or smaller, and accordingly included deposits of 0.2 mm and smaller. With a median observation time of 10 years and 2 months, women with Nmic (N=427) experienced a significantly worse overall survival (OS) compared with node-negative (Nneg) women (N=4,767) (relative risk (RR)=1.20, 95% CI: 1.01-1.43), irrespective of menopausal status. Women with macrometastases (Nmac) (N=1,765) had significantly worse final outcome than women with Nmic (RR=1.54, 95% CI: 1.29-1.85), irrespective of menopausal status. Multivariate analysis adjusted for patient-, histopathologic-, and loco-regional therapeutic variables showed that cases with Nmic had a significantly higher risk of death relative to Nneg cases (adjusted RR=1.49, 95% CI: 1.18-1.90). Interaction analysis showed that the number of nodes examined had a significant impact on adjusted relative risk of death according to axillary status. Furthermore, the number of nodes involved significantly influenced adjusted risk of death in the Nmic compared to the Nmac series. In conclusion, the results of the present study revealed worse final outcome in women with Nmic compared with Nneg, where all Nmic cases received adjuvant systemic treatment. Interaction analysis showed that the number of retrieved axillary nodes and the number of affected nodes had a different influence on survival related to axillary status. The different risk pattern in Nmic vs Nmac patients indicates that Nmic cases do not show the traditional risk pattern as revealed by the Nmac cases, in which increasing number of positive nodes is associated with an orderly increasing adjusted RR.

Entities:  

Mesh:

Year:  2007        PMID: 17614850     DOI: 10.1111/j.1600-0463.2007.apm_442.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  11 in total

1.  Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases.

Authors:  Holm Eggemann; Atanas Ignatov; Madeleine Hetterich; Michael Gerken; Olaf Ortmann; Elisabeth C Inwald; Monika Klinkhammer-Schalke
Journal:  Breast Cancer Res Treat       Date:  2021-03-15       Impact factor: 4.872

2.  Prognosis and Chemotherapy Use in Breast Cancer Patients with Multiple Lymphatic Micrometastases: An NCDB Analysis.

Authors:  Roi Weiser; Efstathia Polychronopoulou; Waqar Haque; Sandra S Hatch; Jing He; Suimin Qiu; Avi Markowitz; William J Gradishar; Yong-Fang Kuo; V Suzanne Klimberg
Journal:  Ann Surg Oncol       Date:  2021-07-11       Impact factor: 5.344

3.  Sentinel lymph node biopsy in breast cancer: predictors of axillary and non-sentinel lymph node involvement.

Authors:  Hakan Postacı; Baha Zengel; Ulkem Yararbaş; Adam Uslu; Nuket Eliyatkın; Göksever Akpınar; Fevzi Cengiz; Raika Durusoy
Journal:  Balkan Med J       Date:  2013-12-01       Impact factor: 2.021

Review 4.  Clinical evidence of breast cancer micrometastasis in the era of sentinel node biopsy.

Authors:  Noriaki Wada; Shigeru Imoto
Journal:  Int J Clin Oncol       Date:  2008-02-29       Impact factor: 3.402

5.  Lymphangiogenesis and lymphatic metastasis in breast cancer.

Authors:  Sophia Ran; Lisa Volk; Kelly Hall; Michael J Flister
Journal:  Pathophysiology       Date:  2009-12-24

6.  Issues related to sentinel lymph node assessment in the management of breast cancer-what are relevant in pathology reports?

Authors:  Patricia Tai; Kurian J Joseph; Edward Yu
Journal:  Patholog Res Int       Date:  2011-03-15

7.  Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.

Authors:  Quinci Romero; Pär-Ola Bendahl; Marie Klintman; Niklas Loman; Christian Ingvar; Lisa Rydén; Carsten Rose; Dorthe Grabau; Signe Borgquist
Journal:  BMC Cancer       Date:  2011-08-07       Impact factor: 4.430

8.  Changes in glycoprotein expression between primary breast tumour and synchronous lymph node metastases or asynchronous distant metastases.

Authors:  Emila Kurbasic; Martin Sjöström; Morten Krogh; Elin Folkesson; Dorthe Grabau; Karin Hansson; Lisa Rydén; Sofia Waldemarson; Peter James; Emma Niméus
Journal:  Clin Proteomics       Date:  2015-05-12       Impact factor: 3.988

9.  Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors.

Authors:  Sophia Ran; Kyle E Montgomery
Journal:  Cancers (Basel)       Date:  2012-06-27       Impact factor: 6.639

10.  The effect of post mastectomy radiation therapy on survival in breast cancer patients with N1mic disease.

Authors:  Mausam Patel; Chenghui Li; Julia H Aronson; Cole M Howie; Sanjay Maraboyina; Arpan V Prabhu; Thomas Kim
Journal:  Breast       Date:  2020-03-06       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.